SS-31 vs Humanin
Both SS-31 and Humanin are used for mitochondrial and longevity. Here's how their evidence, dosing, and regulatory status actually compare.
SS-31
Evidence B+Elamipretide (SS-31)
A cell-permeable tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Investigated for primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.
View full SS-31 profile →Humanin
Evidence BHumanin (HN)
A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.
View full Humanin profile →Side-by-Side
| Attribute | SS-31 | Humanin |
|---|---|---|
| Evidence Grade | B+ | B |
| FDA Status | Not FDA-approved — Phase 3 trials for primary mitochondrial myopathy | Not FDA-approved — mitochondrial-derived peptide research compound |
| Typical Dose | Trial range: 40 mg subcutaneous daily | Research range: 0.5–1 mg subcutaneous (rare clinical use) |
| Clinics Indexed | 29 | 5 |
| Categories | mitochondrial, longevity | mitochondrial, longevity, neuroprotection |
Key reported benefits — SS-31
- ✓Mitochondrial cardiolipin support
- ✓ATP production
- ✓Reduced oxidative damage
Key reported benefits — Humanin
- ✓Cytoprotection
- ✓Anti-amyloid effects
- ✓Insulin sensitization
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.